ArticleTranslational vision science & technology2026
Eye Drop Development of Anti-VEGF Therapeutics by Ocular Penetrating Carrier to the Posterior Region of the Eye.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop an eye drop to deliver therapeutic antibodies, such as aflibercept, into the eye to avoid invasive intravitreal injection (IVT). Methods: We modified and screened cell penetrating peptides (CPPs) for enhanced ocular penetration of large molecule anti-VEGF drugs via eye drop. Modifications to make ocular penetrating carriers (OPCs) included amino acid substitutions, deletions, and multimerization. OPC activity was determined by measuring intraocular levels of aflibercept alone or with anti-Ang2 after formulation with OPC and eye drop application onto mouse eyes. To determine if the aflibercept/OPC eye drop can penetrate large animal eyes in vivo, we applied 50 µg eye drops onto pig eyes. The efficacy of aflibercept/OPC eye drop (20 µg, five drops per day) was determined in a mouse model of laser induced choroidal neovascularization (CNV) and compared to IVT injection of aflibercept. Results: OPC-formulated eye drops improved intraocular delivery of aflibercept up to sixfold in mouse eyes compared to a previously published CPP. In a mouse model of CNV, aflibercept/OPC eye drop treatment decreased vascular leakage, lesion volume, and CNV area by 20% to 50%. The efficacy of aflibercept/OPC eye drop treatment was similar to IVT injection of aflibercept (20 µg). Intraocular penetration of select OPCs was confirmed in pig eyes. Additionally, we demonstrated that a single OPC eye drop can deliver two different protein therapeutics into the eye. Conclusions: Aflibercept/OPC application demonstrates efficacy comparable to IVT injections in a mouse CNV model, supporting its potential as an alternative non-invasive delivery method into the posterior segment. Translational Relevance: OPC eye drop delivery of large molecule therapeutics for AMD, DR, and DME is a noninvasive delivery method that could improve patient adherence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.